TG Therapeutics Soars Nearly 18% as Strong Q4 Results Fuel Growth Optimism

Biopharma firm TG Therapeutics sees stock surge as revenue beats estimates and plans for new Briumvi trial take shape

Mar 03, 2025

Summary

TG Therapeutics jumps 17.95% after strong Q4 earnings beat and 2025 revenue guidance exceeding expectations, fueling investor confidence

TG Therapeutics (TGTX, Financial) shares were up 17.95% at $35.49, gaining $5.40 as of 12:14 PM ET Monday, after the company issued 2025 revenue guidance above expectations and posted a strong Q4 beat.

The biopharma company expects 2025 revenue of ~$540 million, slightly above the $534.45 million consensus estimate. In Q4 2024, revenue came in at $108.19 million, surpassing expectations of $100.67 million.

Adding to investor optimism, TG Therapeutics plans to start a pivotal trial for a subcutaneous version of its multiple sclerosis therapy, Briumvi (ublituximab), by mid-year. The stock has surged over 50% in the past six months, reflecting strong growth momentum as investors remain bullish on the company's potential.

Disclosures

I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.